Wolzt M - Search Results

1

Angiotensin inhibition stimulates PPARgamma and the release of visfatin.

Storka A, Vojtassakova E, Mueller M, Kapiotis S, Haider DG, Jungbauer A, Wolzt M. Storka A, et al. Among authors: wolzt m. Eur J Clin Invest. 2008 Nov;38(11):820-6. doi: 10.1111/j.1365-2362.2008.02025.x. Eur J Clin Invest. 2008. PMID: 19021699

2

Influence of angiotensin II on circulating adhesion molecules and blood leukocyte count in vivo.

Krejcy K, Eichler HG, Jilma B, Kapiotis S, Wolzt M, Zanaschka G, Gasic S, Schütz W, Wagner O. Krejcy K, et al. Among authors: wolzt m. Can J Physiol Pharmacol. 1996 Jan;74(1):9-14. Can J Physiol Pharmacol. 1996. PMID: 8963958 Clinical Trial.

3

Hemodynamic effects of parathyroid hormone-related peptide-(1-34) in humans.

Wolzt M, Schmetterer L, Dorner G, Zelger G, Entlicher J, Kapiotis S, Eichler HG. Wolzt M, et al. J Clin Endocrinol Metab. 1997 Aug;82(8):2548-51. doi: 10.1210/jcem.82.8.4120. J Clin Endocrinol Metab. 1997. PMID: 9253332 Clinical Trial.

4

Ocular and systemic reactivity to isoprenaline in patients with insulin-dependent diabetes mellitus.

Schmetterer L, Findl O, Strenn K, Fasching P, Zanaschka G, Eichler HG, Wolzt M. Schmetterer L, et al. Among authors: wolzt m. Eur J Clin Invest. 1997 Sep;27(9):750-4. doi: 10.1046/j.1365-2362.1997.1830731.x. Eur J Clin Invest. 1997. PMID: 9352246

5

Cisplatin-induced renal effects and thromboxane A2 receptor blockade.

Dorner GT, Pehamberger H, Kornek G, Steger G, Müller M, Wolzt M, Kletter K, James P, Breiteneder H, Eichler HG, Blöchl-Daum B. Dorner GT, et al. Among authors: wolzt m. Eur J Clin Invest. 1997 Oct;27(10):836-9. doi: 10.1046/j.1365-2362.1997.2060753.x. Eur J Clin Invest. 1997. PMID: 9373762 Clinical Trial.

6

Glucose and insulin exert additive ocular and renal vasodilator effects on healthy humans.

Luksch A, Polak K, Matulla B, Dallinger S, Kapiotis S, Rainer G, Wolzt M, Schmetterer L. Luksch A, et al. Among authors: wolzt m. Diabetologia. 2001 Jan;44(1):95-103. doi: 10.1007/s001250051585. Diabetologia. 2001. PMID: 11206417 Clinical Trial.

7

Endothelin ETA receptor-subtype specific antagonism does not mitigate the acute systemic or renal effects of exogenous angiotensin II in humans.

Bayerle-Eder M, Langenberger H, Pleiner J, Polska E, Mensik C, Eichler HG, Wolzt M, Schmetterer L. Bayerle-Eder M, et al. Among authors: wolzt m. Eur J Clin Invest. 2002 Apr;32(4):230-5. doi: 10.1046/j.1365-2362.2002.00974.x. Eur J Clin Invest. 2002. PMID: 11952807 Clinical Trial.

8

Marked increase in vascular endothelial growth factor concentrations during Escherichia coli endotoxin-induced acute inflammation in humans.

Mittermayer F, Pleiner J, Schaller G, Weltermann A, Kapiotis S, Jilma B, Wolzt M. Mittermayer F, et al. Among authors: wolzt m. Eur J Clin Invest. 2003 Sep;33(9):758-61. doi: 10.1046/j.1365-2362.2003.01192.x. Eur J Clin Invest. 2003. PMID: 12925034 Clinical Trial.

9

Free fatty acids exert a greater effect on ocular and skin blood flow than triglycerides in healthy subjects.

Bayerle-Eder M, Polska E, Kopf A, Roden M, Waldhäusl W, Pleiner H, Wipler B, Wolzt M, Schmetterer L. Bayerle-Eder M, et al. Among authors: wolzt m. Eur J Clin Invest. 2004 Aug;34(8):519-26. doi: 10.1111/j.1365-2362.2004.01383.x. Eur J Clin Invest. 2004. PMID: 15305885 Clinical Trial.

10

Simvastatin prevents vascular hyporeactivity during inflammation.

Pleiner J, Schaller G, Mittermayer F, Zorn S, Marsik C, Polterauer S, Kapiotis S, Wolzt M. Pleiner J, et al. Among authors: wolzt m. Circulation. 2004 Nov 23;110(21):3349-54. doi: 10.1161/01.CIR.0000147774.90396.ED. Epub 2004 Nov 1. Circulation. 2004. PMID: 15520323 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

377 results

Search Page

Filters